Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

0 of 6 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

2(40.0%)

Phase 3

1(20.0%)

Phase 2

1(20.0%)

N/A

1(20.0%)

5Total

Phase 4(2)

Phase 3(1)

Phase 2(1)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT01277315Phase 2Completed

Safety and Tolerability of Anakinra in Combination With Riluzol in Amyotrophic Lateral Sclerosis

Role: collaborator

NCT02555540Phase 4Completed

Placebo Controlled Study to Generate Data Characterising Safety Parameters and Immune Responses

Role: collaborator

NCT02523287Phase 4Completed

Placebo Controlled Study to Generate Data Characterising Clinical Events, Physiological Responses and Immune Responses

Role: collaborator

NCT04439045Phase 3Completed

Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity

Role: collaborator

NCT03284515Completed

Vaccination In Pregnancy Gene Signature: VIP Signature Study

Role: collaborator

NCT02368327Not ApplicableCompleted

Gene Expression Profiles in Muscle After Immunisation

Role: collaborator

NCT01112592Unknown

NETs Formation in Patients With Recurrent Pyogenic Infections (NETS)

Role: collaborator

NCT01533779Unknown

Neutrophil Extracellular Traps (NETs) Formation Following Chemotherapy and Their Role in Antitumor Activity

Role: collaborator

NCT01491230Unknown

Neutrophil Extracellular Traps Formation Post-hematopoietic Stem Cell Transplantation

Role: collaborator

All 9 trials loaded